In Brief This Week: Bio-Rad; Fitch, Abbott; Gentris; Indiana Biosciences Research Institute; Strand Life Sciences; Oncospire Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said in its recently filed Form 10-Q that it identified errors in financial statements starting in 2008 through the second quarter of 2013 related to the valuation of finished goods inventory in the company's Life Science segment. It expensed inventory in amounts greater than actual costs for non-sales transactions. To correct for the errors, it has increased net income in full-year 2008 by $600,000; in 2009 by $800,000; in 2010 by $700,000; in 2011 by $800,000; and in 2012 by $1.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.